Before the programme, the company had occasional interactions with startups — but no structured model for turning those connections into sustained, high-impact collaborations.

The challenge was to scale the capacity to innovate in an open, agile, and structured way across critical therapeutic areas — rare and complex diseases that, while affecting a small patient population, carry profound physical, emotional, and social consequences, and demand entirely new approaches to diagnosis, treatment adherence, and long-term monitoring.